ClinicalTrials.gg
CompletedNCT02073461Updated Mar 28, 2017Results posted

Efficacy and Safety Study of 2 Different Concentrations of CD1579 Gels Versus Vehicle in the Treatment of Acne Vulgaris.

A Phase 2 interventional study of CD1579 2.5% and CD1579 5% in Acne Vulgaris, sponsored by Galderma R&D. Completed at 6 sites in Japan. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2017-03-28.

Sponsored by Galderma R&D (part of Galderma Group AG) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
236
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 33 studies testing Benzoyl Peroxide in Acne Vulgaris — none open to participants now, 1 under way, none of them phase 3. Benzoyl Peroxide · Acne Vulgaris.

Enrollment
14th of 33
236 · median 90
Started
2014
the only one that year
Phase 2
2 of 33
none open now
Registered
24th of 33
by date
Lead sponsor
7 of 33
Galderma R&D

Among the 33 studies testing Benzoyl Peroxide in Acne Vulgaris, this one is the 14th largest by enrollment, is the only one that started in 2014, is one of 2 in phase 2, and was the 24th registered.

Acne Vulgaris

791 studies on the registry are indexed under Acne Vulgaris; 93 are open to participants now.

Browse Acne Vulgaris studies →

Open to participants now

None of the 33 studies testing Benzoyl Peroxide in Acne Vulgaris is open now. The open studies under Acne Vulgaris, anywhere →

About Benzoyl Peroxide

Benzoyl Peroxide: first FDA approval 1984 (BENZAMYCIN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 46 Acne Vulgaris studies recruiting now, 16 (35%) set no upper age limit and 29 (63%) stop at 75 or younger; 21 take children under 18; 17 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 33 studies testing Benzoyl Peroxide in Acne Vulgaris as a file.
02

Study summary

This study is to assess the efficacy and safety of two concentrations of CD1579 (2.5% and 5%) versus vehicle in the treatment of acne vulgaris in the Japanese patients.

03

Conditions studied

  • Acne Vulgaris

Browse trials for

Keywords

  • Acne Vulgaris
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women at the age of 12 or older at the Screening visit.
  • Those with clinical diagnosis of acne vulgaris with more than 20 noninflammatory lesions (open and closed comedones) and 12 to 100 (inclusive) inflammatory lesions (papules, pustules and nodules) on the face (forehead, both cheeks, nose and chin).

Exclusion criteria

Exclusion Criteria:

  • Those with more than two nodular acne lesions or any cysts.
  • Those with the diagnosis of any acne conglobata, any acne fulminans, any chloracne, or any drug induced acne.
  • Those who have abnormal findings or conditions on skin other than acne such as atopic dermatitis, perioral dermatitis, or rosacea that potentially interfere with study assessments according to Investigator's judgment
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
236 participants (actual)

Study arms

  • Experimental
    CD1579 2.5%

    Benzoyl Peroxide 2.5%

    Drug: CD1579 2.5%

  • Experimental
    CD1579 5%

    Benzoyl Peroxide 5%

    Drug: CD1579 5%

  • Placebo comparator
    Vehicle

    Vehicle

    Drug: Vehicle

Interventions

  • DrugCD1579 2.5%

    Also known as: Benzoyl Peroxide 2.5%

  • Also known as: Benzoyl Peroxide 5%

  • DrugVehicle
06

What researchers measure

Primary outcomes

  1. Percent Changes From Baseline in Total Lesion Counts

    Median percent reductions from Baseline in total lesion count (ITT-LOCF)

    Time frame: Baseline - Week 12

Secondary outcomes

  1. Percent of Subjects With Adverse Events

    Adverse events which were observed in 5% or more patients with either group are listed.

    Time frame: up to 12 weeks

  2. Local Tolerability (Erythema)

    Highest severity of local tolerability scores worse than Baseline

    Time frame: 12 weeks

  3. Local Tolerability (Scaling)

    Highest severity of local tolerability scores worse than Baseline

    Time frame: 12 weeks

  4. Local Tolerability (Dryness)

    Highest severity of local tolerability scores worse than Baseline

    Time frame: 12 weeks

  5. Local Tolerability (Pruritus)

    Highest severity of local tolerability scores worse than Baseline

    Time frame: 12 weeks

  6. Local Tolerability (Stinging/Burning)

    Highest severity of local tolerability scores worse than Baseline

    Time frame: 12 weeks

07

Results

Posted Nov 3, 2016

Participant flow

Participant flow — Overall Study
MilestoneCD1579 2.5%CD1579 5%Vehicle
Started797879
Completed757778
Not completed411

Outcome measures

PrimaryPercent Changes From Baseline in Total Lesion Counts

Median percent reductions from Baseline in total lesion count (ITT-LOCF)

Time frame:
Baseline - Week 12
Reported as:
Median · percent change
Percent Changes From Baseline in Total Lesion Counts
percent changeCD1579 2.5%CD1579 5%Vehicle
Percent Changes From Baseline in Total Lesion Counts58.3 (-243.7 to 100)65.9 (-41.0 to 100)25.5 (-180.7 to 88.9)
SecondaryPercent of Subjects With Adverse Events

Adverse events which were observed in 5% or more patients with either group are listed.

Time frame:
up to 12 weeks
Reported as:
Number · percentage of participants
Percent of Subjects With Adverse Events
percentage of participantsCD1579 2.5%CD1579 5%Vehicle
% of subjects with AEs43.039.732.9
Nasopharyngitis12.714.113.9
Headache10.11.38.9
Dysmenorrhea6.33.83.8
SecondaryLocal Tolerability (Erythema)

Highest severity of local tolerability scores worse than Baseline

Time frame:
12 weeks
Reported as:
Number · participants
Local Tolerability (Erythema)
participantsCD1579 2.5%CD1579 5%Vehicle
Mild12185
Moderate330
Severe010
SecondaryLocal Tolerability (Scaling)

Highest severity of local tolerability scores worse than Baseline

Time frame:
12 weeks
Reported as:
Number · participants
Local Tolerability (Scaling)
participantsCD1579 2.5%CD1579 5%Vehicle
Mild15258
Moderate471
SecondaryLocal Tolerability (Dryness)

Highest severity of local tolerability scores worse than Baseline

Time frame:
12 weeks
Reported as:
Number · participants
Local Tolerability (Dryness)
participantsCD1579 2.5%CD1579 5%Vehicle
Mild203310
Moderate260
SecondaryLocal Tolerability (Pruritus)

Highest severity of local tolerability scores worse than Baseline

Time frame:
12 weeks
Reported as:
Number · participants
Local Tolerability (Pruritus)
participantsCD1579 2.5%CD1579 5%Vehicle
Mild20136
Moderate671
Severe120
SecondaryLocal Tolerability (Stinging/Burning)

Highest severity of local tolerability scores worse than Baseline

Time frame:
12 weeks
Reported as:
Number · participants
Local Tolerability (Stinging/Burning)
participantsCD1579 2.5%CD1579 5%Vehicle
Mild19294
Moderate671

Adverse events

Collected over 12 weeks. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
CD1579 2.5%—0/79 (0%)34/79 (43%)
CD1579 5%—0/78 (0%)31/78 (39.7%)
Vehicle—1/79 (1.3%)26/79 (32.9%)
Most frequent serious events
Most frequent serious events
EventCD1579 2.5%CD1579 5%Vehicle
Compression fractureInjury, poisoning and procedural complications0/790/781/79
Most frequent other events
Showing 10 of 47
Most frequent other events
EventCD1579 2.5%CD1579 5%Vehicle
NasopharyngitisInfections and infestations10/7911/7811/79
HeadacheNervous system disorders8/791/787/79
DysmenorrhoeaReproductive system and breast disorders5/793/783/79
Skin irritationSkin and subcutaneous tissue disorders3/791/780/79
Seasonal allergyImmune system disorders2/792/782/79
Oral herpesInfections and infestations1/792/780/79
EczemaSkin and subcutaneous tissue disorders1/792/780/79
UrticariaSkin and subcutaneous tissue disorders1/792/780/79
Rhinitis allergicRespiratory, thoracic and mediastinal disorders2/790/780/79
Erythema of eyelidEye disorders1/791/780/79

Baseline characteristics

Age, Continuous
Age, Continuous(years)CD1579 2.5%CD1579 5%VehicleTotal
Mean22.1 ± 7.021.1 ± 5.621.0 ± 6.321.4 ± 6.3
Sex: Female, Male
Sex: Female, Male(Participants)CD1579 2.5%CD1579 5%VehicleTotal
Female575145153
Male22273483
Region of Enrollment
Region of Enrollment(participants)CD1579 2.5%CD1579 5%VehicleTotal
Japan797879236
08

Study locations

6 sites
  • Galderma investigational site
    Amagasaki, Hyogo, Japan
  • Galderma investigational site
    Kobe, Hyogo, Japan
  • Galderma investigational site
    Nakano, Tokyo, Japan
  • Galderma investigational site
    Shibuya, Tokyo, Japan
  • Galderma investigational site
    Shinjuku, Tokyo, Japan
  • Galderma investigational site
    Fukuoka, Japan
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2014, a primary completion of Oct 2014 and a completion of Oct 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2016, 2 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 20, 2014
First posted
Feb 27, 2014
Start
Mar 2014
Primary completionActual
Oct 2014
CompletionActual
Oct 2014
Results first posted
Nov 3, 2016
Last update
Mar 28, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 28, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02073461
Lead sponsor
Galderma R&D
Responsible party
Sponsor
First posted
Feb 27, 2014
Start date
Mar 2014
Primary completion
Oct 2014
Completion
Oct 2014
Results posted
Nov 3, 2016
Last update
Mar 28, 2017

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Benzoyl Peroxide

Start the discussion